Cowen & Co. analyst Ritu Baral maintained a Buy rating on Alnylam Pharma (ALNY) today and set a price target of $147. The company’s shares opened today at $75.05.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 28.1% and a 54.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $128.40 average price target, representing a 71.1% upside. In a report issued on April 26, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $138 price target.
See today’s analyst top recommended stocks >>
Based on Alnylam Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $182 million. In comparison, last year the company had a GAAP net loss of $141 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
